98140-03-5

Usage

Uses

Used in Pharmaceutical Industry:
6-chloro-N4-ethylpyrimidine-4,5-diamine is used as a key intermediate in the synthesis of various pharmaceuticals for its potential role in developing antiviral and anticancer drugs. Its unique structure allows for the creation of molecules that can target specific biological pathways, making it a valuable component in medicinal chemistry.
Used in Agrochemical Industry:
6-chloro-N4-ethylpyrimidine-4,5-diamine is also utilized as a building block in the development of agrochemicals, such as herbicides and pesticides. Its chemical properties enable the design of effective agents that can protect crops from pests and diseases, thereby contributing to increased agricultural productivity.
Used in Industrial Applications:
Due to its distinctive chemical structure, 6-chloro-N4-ethylpyrimidine-4,5-diamine may have other industrial applications beyond pharmaceuticals and agrochemicals. Its versatility in chemical reactions and potential to form new compounds make it a candidate for use in various industrial processes, although specific applications would require further research and development.

Upstream product

• 5413-85-4 5-amino-4,6-dichloropyridimine 
• 75-04-7 ethylamine 
• 25710-24-1 4-Chlor-6-aethylamino-5-nitropyrimidin 
• 4316-98-7 6-chloro-4,5-diaminopyrimidine 
• 557-66-4 ethanamine hydrochloride 

Downstream Products

• 5462-86-2 6-chloro-9-ethyl-9H-purine 
• 101080-16-4 N⁴-ethyl-pyrimidine-4,5-diyldiamine 
• 492464-38-7 6-ethoxy-8-methyl-9-(ethyl)-9H-purine 
• 868163-66-0 6-chloro-9-ethyl-8-phenyl-9H-purine 
• 1610711-25-5 N-(3-{[9-ethyl-8-(2-methylpyrimidin-5-yl)-9H-purin-6-yl]amino}cyclohexyl)-1,3-oxazole-4-carboxamide 
• 1610706-31-4 N-((1S,3S)-3-{[9-ethyl-8-(2-methylpyrimidin-5-yl)-9H-purin-6-yl]amino}cyclohexyl)-1,3-oxazole-4-carboxamide 
• 1610706-30-3 N-((1R,3R)-3-{[9-ethyl-8-(2-methylpyrimidin-5-yl)-9H-purin-6-yl]amino}cyclohexyl)-1,3-oxazole-4-carboxamide 
• 1610703-98-4 9-ethyl-8-(2-methylpyrimidin-5-yl)-N-[(3S)-1-(phenylacetyl)pyrrolidin-3-yl]-9H-purin-6-amine 

Relevant academic research and scientific papers

Evaluation of WO2014075392 and WO2014075393, Merck's first PI3Kδ inhibitor filings

Introduction: There is considerable interest in the development of selective PI3Kδ inhibitors for the treatment of inflammatory diseases and haematological cancers. Merck has no previous filings in this field but licensed Exelixis' programme, including its lead compound XL-499, in December 2011.Areas covered: Both applications claim novel 9-alkyl-6,8-disubstituted purine derivatives as selective δ inhibitors for the treatment of asthma, obstructive airways disease, arthritis and cancer. The two applications differ in the range of exemplified substituents, the first focusing on 8-heteroaryl substituted purines, the second on 8-aminopurine derivatives. Many of the exemplified compounds have IC50 values a number having sub-nanomolar potency.Expert Opinion: The compounds appear to be XL-499 derivatives, some of which are more potent than XL-499. The compounds claimed by Merck are some of the most potent PI3Kδ inhibitors yet described but it is unclear whether a development compound has been identified.

3,4-dichloroisothiazole heterocyclic purine derivatives as well as preparation method and application thereof

The invention provides a 3,4-dichloroisothiazole bipurine derivative as well as a preparation method and application thereof, and particularly relates to the 3,4-dichloroisothiazole bipurine derivative of which the chemical structural general formula is s

Design, Synthesis, and Evaluation of Novel Isothiazole-Purines as a Pyruvate Kinase-Based Fungicidal Lead Compound

Target identification is one of the most important bases for novel pesticide development; pyruvate kinase (PK) was discovered as a potent fungicide target in our previous studies. To continue the PK-based fungicide development, novel isothiazole-purine derivatives were rationally designed and synthesized. Bioassay results showed that compound 5ai displayed excellent in vitro activity against Rhizoctonia solani with an EC50 of 1.5 μg/mL, which was superior to those of positive controls diflumetorim with its EC50 of 19.8 μg/mL and PK-based lead YZK-C22 with its EC50 of 4.2 μg/mL. Compounds 3b (5.2 μg/mL) and 3c (4.5 μg/mL) displayed better activities against Gibberella zeae with their EC50s falling between 4.0 and 5.5 μg/mL, while YZK-C22 showed an EC50 of 6.4 μg/mL. In addition, 5ah exhibited promising in vivo activity against Erysiphe graminis and Puccinia sorghi Schw. with 100% efficacy at 10 μg/mL and 90% efficacy at 2 μg/mL against P. sorghi Schw. Compound 5ai showed good PK inhibitory activity with an IC50 of 38.8 μmol/L, and it was well docked into the active site of the target enzyme PK, which was slightly more active than YZK-C22 with its IC50 of 42.4 μmol/L. Our studies discovered that isothiazole-purines were PK-based fungicidal leads deserving of further study.

New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases

The synthesis of 9-alkyl substituted adenine derivatives presenting aromatic groups and cycloalkyl rings in 8- and N6-position, respectively, is reported. The compounds were tested with radioligand binding studies showing, in some cases, a low

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

Provided are compounds of formula (I) or a pharmaceutically acceptable salts or stereoisomer thereof, which are PI3K-delta inhibitors, and are useful for the treatment of PI3K-delts-mediated diseases such as inflammation, asthma, COPD and cancer.

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

The instant invention provides compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

Provided are compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflamation, asthma, COPD and cancer.

8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands

Importance of making available selective adenosine receptor antagonists is boosted by recent findings of adenosine involvement in many CNS dysfunctions. In the present work a series of 8-bromo-9-alkyl adenines are prepared and fully characterized in radio